{"id":"NCT00770211","sponsor":"Merz Pharmaceuticals GmbH","briefTitle":"IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines","officialTitle":"A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Efficacy and Safety of IncobotulinumtoxinA (Xeomin), Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2009-03","completion":"2009-06","firstPosted":"2008-10-09","resultsPosted":"2011-09-13","lastUpdate":"2011-10-07"},"enrollment":271,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Glabellar Frown Lines"],"interventions":[{"type":"DRUG","name":"IncobotulinumtoxinA (Xeomin) (20 Units)","otherNames":["IncobotulinumtoxinA (Xeomin), also known as 'NT 201' or 'Botulinum toxin type A (150 kD), free from complexing proteins' (20 Units)"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"IncobotulinumtoxinA (Xeomin) (20 Units)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study objective is to show the superior efficacy of IncobotulinumtoxinA (Xeomin) over placebo by evaluation of treatment success analyzing the investigator's rating on the Facial Wrinkle Scale and the patient's assessment on a 4-point scale. 255 female and male patients with moderate to severe glabellar frown lines will be randomized in a 2:1 ratio to receive one injection of IncobotulinumtoxinA (Xeomin) or placebo and will be followed up until day 120.","primaryOutcome":{"measure":"Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's Rating on the Facial Wrinkle Scale and the Patient's Assessment on 4-point Scale","timeFrame":"Baseline to Day 30","effectByArm":[{"arm":"IncobotulinumtoxinA (Xeomin) (20 Units)","deltaMin":87,"sd":null},{"arm":"Placebo","deltaMin":0,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":8,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":182},"commonTop":["Headache","Nasopharyngitis","Sinusitis","Sinus headache","Pharyngitis streptococcal"]}}